Health Canada lukewarm on Vioxx panel findings.
Murray
Sally
S
D002170:Canada; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003657:Decision Making; D017277:Drug Approval; D004345:Drug Industry; D004348:Drug Labeling; D005104:Expert Testimony; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D016365:Liability, Legal; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib